Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Editorial Examines How USAID Programs Used Biblical Lessons To Teach Abstinence In Africa
A recent audit by the U.S. Agency for International Development"s inspector general has "raised questions about several USAID expenditures" on a number of "faith-based" projects initiated during former President George W. Bush"s administration, a Los Angeles Times editorial says. Among other issues, the report highlighted "the use of instructional materials, including biblical references," in an HIV/AIDS prevention program that promoted sexual abstinence in Africa, the editorial continues. It adds that USAID said that it "stopped allowing "religiously infused" curricula after the Justice Department expressed legal qualms."According to the Times, the issue raises several questions, including whether the U.S. Constitution is "violated when U.S. officials abroad ... endorse religious activities in the furtherance of this nation"s foreign policy." It states, "Our answer is no, but policymakers still need to be cautious about mixing religion and diplomacy" (Los Angeles Times, 7/24). Don't forget to buy zoloft online no prescription.

Preventing Road Rage, UK
Figures from the British Institute for Anger Management reveal that the UK already has the worst road rage figures of any European nation, with 80% of drivers saying they"ve been involved in an incident and 1 in 4 admitting to committing an act of road rage themselves. Men are three times more likely to commit an act of aggression than women and over 60% of drivers say they have been intimidated by aggressive tailgating.

generic viagra online


News of the day
Improvement In Long-Term Survival From Abdominal Aortic Aneurysm Repair
Long-term survival for patients undergoing surgical repair of intact abdominal aortic aneurysms has improved in recent decades, according to a Swedish study reported in Circulation: Journal of the American Heart Association.
Mental Health

Abbott Receives CE Mark For Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position

Abbott announced that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter. "XIENCE PRIME leverages and will build upon the outstanding body of clinical evidence from the SPIRIT family of clinical trials. The modified design features of the stent and delivery system are intended to make it easier for physicians to deliver the stent to the treatment area," said Robert Hance, senior vice president, vascular, Abbott. "As part of Abbott"s leadership in drug eluting stents, we are committed to advancing treatment options and look forward to making the innovative XIENCE PRIME stent available to physicians and patients in Europe in the upcoming months." XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott"s market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. In addition, it offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability. XIENCE PRIME uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. XIENCE PRIME is based upon the proven design of the MULTI-LINK(R) family of stents, which is the most widely used stent platform in the world - more than 2 million of Abbott"s cobalt chromium stents have been implanted worldwide. Upon launch in Europe, XIENCE PRIME will be available in an expanded size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions. Abbott"s robust vascular research program includes clinical trials in coronary artery disease and peripheral artery disease. Key products in the vascular pipeline include: the MULTI-LINK 8(TM) Coronary Stent System, a next-generation frontline balloon dilatation catheter, a fully bioabsorbable drug eluting coronary device, and the Omnilink Elite(TM) Peripheral Stent System. The MULTI-LINK 8 Coronary Stent System, the next-generation frontline balloon dilatation catheter, the fully bioabsorbable drug eluting device and the Omnilink Elite Peripheral Stent System are in development and are not available for sale. XIENCE PRIME currently is an investigational device in the United States and not available for sale. About XIENCE V Abbott"s market-leading XIENCE V drug eluting stent is marketed in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan"s Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties. About Abbott Vascular Abbott Vascular, a division of Abbott, is one of the world"s leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products. About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries. Abbott


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009